Advances in informatics have afforded researchers the ability to extrapolate petabytes of human genomics data and translate it into biologically relevant information. However, further translating this information into knowledge can prove challenging. Slavé Petrovski, Vice President and Head of Genome Analytics and Bioinformatics for AstraZeneca’s Centre for Genomics Research, spoke…
List view / Grid view
Filter the results
Detailed knowledge of the human genome can provide us with extensive information about the causes of disease and how patients will respond to treatments. In this article, Pushpanathan Muthuirulan explores the concept of genetic testing and the potential for pharmacogenomic testing to transform healthcare.
A collapsible basket technology has been developed to significantly accelerate the analysis process when scientists are developing new medicines.
A new imaging technique, which has revealed 3D forces exerted by tiny cell clusters, could help scientists understand how tissue forms, how wounds heal or how tumours spread.
New technology is for the first time enabling scientists to analyse the individual behaviour of millions of different cells living inside lab-grown tumours, which could lead to new personalised cancer treatments.
Scientists have produced hundreds of organoids which they say could be produced on a large-scale as a low-cost tissue model to help research and test new medulloblastoma therapies.
Researchers investigating childhood leukaemia have discovered that increasing MLL gene expression in iPSCs drives hematopoietic stem cell production, so could be the target of new therapies.
Lab-grown brain organoids from patients’ glioblastomas could be useful models to rapidly test and identify effective personalised treatments, find researchers.
Humanised immune system (HIS) models have enabled numerous in vivo evaluations of immuno-modulating biologic drugs and ongoing improvements continue to extend their utility. Paul Volden explores the application of HIS models in precision and personalised medicine with a focus on biologics, including how HIS models are used, why they are…
The number of immuno-oncology active agents has seen a tremendous boost during the past three years. The 2019 global immuno-oncology pipeline consists of almost 3,900 agents, making immuno-oncology discovery very attractive.
This issue includes a discussion on the future of high-throughput screening through collaboration, an analysis of mass spectrometry as a structural biology tool and an exploration of the challenges of hit-to-lead when researching tropical diseases. Also in the issue are articles on immuno-oncology and assays.
A pioneering team of scientists from Rice University has discovered that a particular combination of chemotherapeutics, including mitocans that target mitochondria, form a powerful treatment for acute myeloid leukaemia patients.
The involvement of clathrin in the development of liver cancer has been described for the first time, which could lead to more targeted therapy.
A new algorithm has been developed which personalises which cancer mutations are best targets for immunotherapy.
A study has demonstrated that blocking certain receptors in mice reduced Ewing sarcoma growth and metastasis, which could be used within future treatments.